{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:20:51Z","timestamp":1782224451678,"version":"3.54.5"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.retram.2023.103427","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:28:30Z","timestamp":1698150510000},"page":"103427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-3663","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Daudignon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-5372","authenticated-orcid":false,"given":"Wendy","family":"Cuccuini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-6702","authenticated-orcid":false,"given":"Claire","family":"Bracquemart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Quilichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-344X","authenticated-orcid":false,"given":"Dominique","family":"Penther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2023.103427_bib0001","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0002","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2019004309","article-title":"Risk factors in multiple myeloma: is it time for a revision?","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the risk-stratified treatment of multiple myeloma","volume":"3","author":"Davies","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.retram.2023.103427_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0006","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0008","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","article-title":"Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?","volume":"126","author":"Chretien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0009","first-page":"588","article-title":"Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytog\u00e9n\u00e9tique h\u00e9matologique (GFCH)","volume":"74","author":"Daudignon","year":"2016","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1016\/j.retram.2023.103427_bib0010","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41467-017-00638-w","article-title":"Expressed fusion gene landscape and its impact in multiple myeloma","volume":"8","author":"Cleynen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2023.103427_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.538126","article-title":"What multiple myeloma with t(11;14) should be classified into in novel agent era: standard or intermediate risk?","volume":"10","author":"Gao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.retram.2023.103427_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.934008","article-title":"Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation","volume":"12","author":"Diamantidis","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2023.103427_bib0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2023.103427_bib0016","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0017","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0018","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1038\/bcj.2014.29","article-title":"The role of epigenetics in the biology of multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.retram.2023.103427_bib0021","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0022","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-09-2801","article-title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript","volume":"101","author":"Santra","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0023","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2023.103427_bib0024","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.exphem.2014.11.004","article-title":"Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment","volume":"43","author":"An","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.retram.2023.103427_bib0027","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0028","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.6","article-title":"t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs","volume":"5","author":"Narita","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0029","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0031","first-page":"611","article-title":"Combination of genetic aberration with international staging system classification for stratification of asian multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Byun","year":"2019","journal-title":"Vivo Athens Greece"},{"key":"10.1016\/j.retram.2023.103427_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.25758","article-title":"A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma","volume":"95","author":"Goldman-Mazur","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2023.103427_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-020-0307-4","article-title":"Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents","volume":"10","author":"Mina","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0034","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (r2-iss) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.retram.2023.103427_bib0036","unstructured":"Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients n.d. https:\/\/www.tandfonline.com\/doi\/epdf\/10.1080\/10428194.2020.1749605?needAccess=true&role=button (accessed April 4, 2023)."},{"key":"10.1016\/j.retram.2023.103427_bib0037","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.retram.2023.103427_bib0039","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","article-title":"Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2023.103427_bib0041","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.retram.2023.103427_bib0042","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0043","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0044","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0045","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.retram.2023.103427_bib0046","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0047","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0048","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.retram.2023.103427_bib0049","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0050","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0051","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0052","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1038\/bcj.2017.76","article-title":"Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival","volume":"7","author":"Chin","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0053","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0054","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.retram.2023.103427_bib0056","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0057","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2023.103427_bib0058","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0059","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jncimonographs\/lgn011","article-title":"Characterization of MYC translocations in multiple myeloma cell lines","author":"Dib","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.retram.2023.103427_bib0060","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2012-08-445262","article-title":"MYC addiction: a potential therapeutic target in MM","volume":"120","author":"Kuehl","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0061","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.retram.2023.103427_bib0062","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.retram.2023.103427_bib0063","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2023.103427_bib0064","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gcc.20670","article-title":"Frequent upregulation of MYC in plasma cell leukemia","volume":"48","author":"Chiecchio","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.retram.2023.103427_bib0065","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2023.103427_bib0066","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.retram.2023.103427_bib0067","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.retram.2023.103427_bib0068","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","article-title":"Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0069","doi-asserted-by":"crossref","first-page":"14671","DOI":"10.1038\/s41598-021-93835-z","article-title":"Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities","volume":"11","author":"Kriegova","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.retram.2023.103427_bib0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a pathogenic driver of multiple myeloma","volume":"123","author":"Maura","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.retram.2023.103427_bib0071","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0072","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000520312","article-title":"Multiple myeloma: molecular pathogenesis and disease evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.retram.2023.103427_bib0073","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2023.103427_bib0074","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.3390\/cancers14205169","article-title":"NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial","volume":"14","author":"Rosa-Rosa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.retram.2023.103427_bib0076","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.retram.2023.103427_bib0077","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2023.103427_bib0078","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1097\/HS9.0000000000000857","article-title":"The R2-ISS in a multicenter cohort of chinese patients with newly diagnosed multiple myeloma","volume":"7","author":"Yang","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.retram.2023.103427_bib0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0079","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjh.18536","article-title":"The second revision of the international staging system (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: real world data results in an Australian and New Zealand population","volume":"200","author":"Tan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2023.103427_bib0080","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0081","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0082","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0083","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103427_bib0084","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40164-021-00236-z","article-title":"Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications","volume":"10","author":"Xu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0086","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","article-title":"Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma","volume":"2","author":"Bochtler","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2023.103427_bib0087","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103427_bib0088","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.retram.2023.103427_bib0089","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862300051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862300051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:40:59Z","timestamp":1762821659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862300051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S245231862300051X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2023.103427","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2023.103427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103427"}}